HLB Pharmaceutical Receives Approval for Generic Prostate Cancer Drug... Launch Planned for June
Elbitandi, a Generic Version of Xtandi, Receives Product Approval
HLB Pharmaceutical Accelerates Expansion of Oncology Business Focused on General Hospitals
HLB Pharmaceutical is expanding its oncology business by obtaining approval for a generic drug for prostate cancer treatment.
HLB Pharmaceutical Prostate Cancer Treatment Generic Drug ‘Elbitandi Soft Capsule 40mg’ Product Image. HLB Pharmaceutical
View original imageOn May 14, HLB Pharmaceutical announced that it had received product approval from the Ministry of Food and Drug Safety for Elbitandi Soft Capsule 40mg (active ingredient: enzalutamide), a treatment for metastatic castration-resistant prostate cancer. The company is aiming to launch the product at the end of June.
Elbitandi is a generic version of Xtandi, a prostate cancer treatment by Astellas Pharma Korea. Enzalutamide works by inhibiting androgen receptor signaling and is used for conditions such as metastatic castration-resistant prostate cancer. According to the pharmaceutical market research firm IQVIA, Xtandi recorded domestic sales of 43.2 billion won in 2023 and 43.8 billion won in 2024.
HLB Pharmaceutical plans to expand its oncology business, focusing on general hospitals, following this approval. The company intends to strengthen its portfolio of high value-added specialty drugs, starting with oncology generics and moving on to improved drugs and first generics.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- [Why&Next] Uber and Naver Move to Acquire Baemin... Eyeing Coupang's Top Spot in Commerce
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Shin Dongseok, Executive Director of the Oncology Business Division at HLB Pharmaceutical, said, "We will leverage our general hospital network to facilitate the market entry of Elbitandi and continue to build our business capabilities in the general hospital sector. Since trust in products and prescribing experience are crucial in the oncology field, we will closely monitor the needs of medical professionals and market conditions to establish a stable business foundation."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
